Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.